Literature DB >> 6208120

Monoclonal antibodies defining markers with apparent selectivity for particular haemopoietic cell types may also detect antigens on cells of neural crest origin.

J T Kemshead, J Fritschy, U Asser, R Sutherland, M F Greaves.   

Abstract

Monoclonal antibodies described as reacting with particular subsets of haemopoietic cells were screened against a variety of neuronal cell lines to further investigate their true specificity. While some reagents, e.g., monoclonal anti-cALL (J5), were found only reactive with haemopoietic cells, other monoclonals, e.g., BA1, BA2, NA134, OKT6, and OKT9, also bound to neuronal cells. Further investigation into the cross-reactivity of these antibodies to a variety of neural crest derived cell lines indicated that, with the exception of OKT9, differential binding patterns to different lines were obtained. This suggests that haemopoietic cell subsets and neural crest derived tissues can share similar differentiation antigens. For monoclonals OKT9 and BA2 this observation was confirmed biochemically, showing that it is not just antigenic determinants but similar molecular weight cell surface antigens that are shared between subsets of the two major cell types. A similar analysis using monoclonal antibodies raised against human neuronal cells or cell lines again indicates that some antigens appear unique to neural tissue while others are shared by haemopoietic cell subsets.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6208120     DOI: 10.1089/hyb.1.1982.1.109

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  12 in total

Review 1.  Immunoconjugates: applications in targeted drug delivery for cancer therapy.

Authors:  B P Ram; P Tyle
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

Review 2.  The immunobiology of human gliomas.

Authors:  V Piguet; A C Diserens; S Carrel; J P Mach; N de Tribolet
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Is there a role for radioimmunolocalization in diagnosis of intracranial malignancies?: discussion paper.

Authors:  J T Kemshead; D H Jones; A Goldman; R B Richardson; H B Coakham
Journal:  J R Soc Med       Date:  1984-10       Impact factor: 5.344

4.  Construction of an antigenic map for human B-cell precursors.

Authors:  G B Melink; T W LeBien
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

5.  Monoclonal antibodies against differentiation antigens of myelopoiesis.

Authors:  W Knapp
Journal:  Blut       Date:  1982-11

6.  Monoclonal antibody BA-1 to the human B lymphocyte marker CD24 recognizes a sialic acid (N-acetylneuraminic acid) dependent epitope in multi-valent display on peptide.

Authors:  H Mehmet; M Larkin; P W Tang; T W Lebien; T Feizi
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

7.  Monoclonal antibodies VIB-E3, IB5 and HB9 to the leucocyte/epithelial antigen CD24 resemble BA-1 in recognizing sialic acid-dependent epitope(s). Evidence that VIB-E3 recognizes NeuAc alpha 2-6GalNAc and NeuAc alpha 2-6Gal sequences.

Authors:  M Larkin; W Knapp; M S Stoll; H Mehmet; T Feizi
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

8.  Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline.

Authors:  E Weber; H P Lehmann; A G Beck-Sickinger; E J Wawrzynczak; R Waibel; G Folkers; R A Stahel
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines.

Authors:  T Akashi; T Shirasawa; K Hirokawa
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  Very late activation antigens (VLA) are human leukocyte-neuronal crossreactive cell surface antigens.

Authors:  K D Pischel; H G Bluestein; V L Woods
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.